Please login to the form below

Not currently logged in
Email:
Password:

DP2 antagonist

This page shows the latest DP2 antagonist news and features for those working in and with pharma, biotech and healthcare.

Novartis ditches oral asthma drug after disappointing phase 3 readout

Novartis ditches oral asthma drug after disappointing phase 3 readout

Its safe to say that Novartis can no longer bet on the DP2 antagonist to generate any kind of growth following these results. ... The biotech has a DP2 antagonist – GB001 – in two phase 2 studies, with another one planned, across eosinophilic asthma,

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Frontera Group

Welcome to Frontera Group, where our agencies immerse you in the world of the patient...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics